TCGA-BH-A18M-01A-11R-A12D-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 74
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- INTERFERON_ALPHA_RESPONSE+0.480
- UV_RESPONSE_DN+0.480
- TGF_BETA_SIGNALING+0.460
- ESTROGEN_RESPONSE_EARLY+0.350
- INTERFERON_GAMMA_RESPONSE+0.320
- TNFA_SIGNALING_VIA_NFKB+0.310
- HEDGEHOG_SIGNALING+0.300
- WNT_BETA_CATENIN_SIGNALING+0.270
- ANDROGEN_RESPONSE+0.260
Top 10 suppressed
- E2F_TARGETS-0.260
- G2M_CHECKPOINT-0.240
- OXIDATIVE_PHOSPHORYLATION-0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- MYC_TARGETS_V2-0.230
- SPERMATOGENESIS-0.190
- GLYCOLYSIS-0.130
- ALLOGRAFT_REJECTION-0.110
- MYC_TARGETS_V1-0.110
- DNA_REPAIR-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A1-A0SD-01A-11R-A115-07 | — | A | 0.867 |
| 2 | TCGA-AC-A2B8-01A-11R-A17B-07 | — | A | 0.805 |
| 3 | MNG575 | — | — | 0.804 |
| 4 | TCGA-CN-4742-01A-02R-1514-07 | — | — | 0.796 |
| 5 | SRR934720 | — | — | 0.795 |
| 6 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.795 |
| 7 | SRR13780273 | — | cohortMD2 | 0.793 |
| 8 | BS_69V8P8A0 | Neurofibroma | — | 0.791 |
| 9 | TCGA-AR-A24V-01A-21R-A169-07 | — | A | 0.779 |
| 10 | BS_014EVM2D | low-grade glioma | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.480 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |